Randomized trials comparing Telmisartan vs. Valsartan and Losartan 24-hour ambulatory blood pressure control, GLP-1 heart failure outcomes, UKPDS 34 cardiovascular mortality reductions, and statin + ezetimibe ApoB targets. Explore 714 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Walnut consumption may be associated with small reductions in CRP and IL-6 levels, without significant effects on TNF-α or adipokine concentrations. However, these effects are modest, and their clinical relevance remains uncertain.
Inclisiran single-drug treatment provided sustained and effective LDL-C reductions with a favorable safety profile in Chinese adults with low/moderate ASCVD risk.
Triple combination therapy with Val/Aml/CTD demonstrated superior blood pressure reduction and a favorable safety profile in patients with essential high blood pressure inadequately controlled on Val/Aml dual therapy,...
Early acute eGFR changes were common and adversely prognostic in patients with HFpEF.
Tirzepatide reduces high blood pressure-related side effects but increases dose-dependent hypotension risk in patients with T2DM or obesity.
Nearly all studied interventions were more effective than placebo and/or LI in reducing weight.
In patients undergoing elective PCI, the risk of periprocedural ischemic events is adequately captured by the total stent length.
Our findings support the use of dihydropyridine calcium channel blockers as a preferred alternative to β-blockers for the management of high blood pressure in HFpEF.
Our results show the estimated MID for short-term NT-proBNP improvement in PAH and PH-ILD is remarkably similar at 48%.
Tirzepatide 15 mg and CagriSema achieve the greatest weight reduction, including ≥ 20% body weight loss.
Obicetrapib lowered LDL-C, apoB and Lp(a).
With a comparable safety profile across treatment groups, these findings suggest that TEL/AML 20/2.5 is a practical and effective option for high blood pressure management.
In this secondary analysis of the SPARTAN trial, statin use was not associated with improved survival outcomes overall.
Single-pill LDC-ALC achieved BP reductions similar to those with amlodipine and greater than those with losartan single-drug treatment over 8 weeks, with similar short-term tolerability.
In GALACTIC-HF, higher DP levels were independently associated with increased risk of adverse clinical outcomes in patients with reduced ejection fraction.
Low-dose triple single-pill combination of telmisartan/amlodipine/chlorthalidone demonstrated superior BP-lowering efficacy with well-tolerated and comparable safety to standard-dose telmisartan single-drug treatment.
This is the only heart and blood vessel outcomes trial to date that exclusively enrolled patients with statin intolerance, and the largest contemporary study of lipid lowering therapy in females, a group historically...
Very high-intensity and high-intensity statin regimens differed minimally in achieving LDL-C targets, but very high-intensity regimens had higher rates of intolerance-related dose reduction.
In patients with T2D at intermediate risk for HFpEF, dapagliflozin was associated with more favorable changes in left ventricular diastolic function parameters compared with glibenclamide, accompanied by improvements in...
Ezetimibe added to high-intensity statin therapy was well tolerated and resulted in an immediate and robust additional decrease in circulating LDL-C concentrations, with a markedly higher proportion of participants achieving...
At 8 weeks, the least square (LS) mean (SE) change in msSBP was -20.04 (1.46) mm Hg in the Tel/S-Amlo group, compared with -16.44 (1.46) mm Hg in the Tel group (between-group difference -3.60 (1.78) mm.
FDCs significantly improved LDL-C goal attainment compared to AS single-drug treatment in patients with very high ASCVD risk.
Bedtime telmisartan dosage improves nocturnal BP control, but morning dosage more successfully lowers exercise-induced BP spikes.
After ∼4 years, DOR-based regimens were not associated with changes in ASCVD risk scores in PLWH.
CONCLUSION: This meta-analysis identified several risk factors associated with AGA presence and progression, including a family history of AGA, smoking, alcohol consumption, insufficient or poor-quality sleep,...
All the treatments were well tolerated overall.
Low-dose GMRx2 provides superior BP reduction and a well-tolerated safety profile in patients with mild to moderate high blood pressure.
In addition to a significant and sustained day and night-time ambulatory BP reduction, aprocitentan was associated with a higher proportion of patients experiencing dipping pattern normalization and more pronounced BP load...
Semaglutide significantly improves BMI and lipid profiles in PCOS, particularly at higher doses, and in obese patients.
WWI is closely associated with future heart and blood vessel outcomes and TM in patients with T2DM.WWI serves as an autonomous predictor of both future heart and blood vessel events and TM among patients with T2DM,...
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
